tetano
Editor, Senior Moderator
Biochem Biophys Res Commun
. 2024 Nov 3:738:150945.
doi: 10.1016/j.bbrc.2024.150945. Online ahead of print. mRNA encoding antibodies against hemagglutinin and nucleoprotein prevents influenza virus infection in vitro
Y A Zabrodskaya[SUP] 1 [/SUP], N V Gavrilova[SUP] 2 [/SUP], E A Elpaeva[SUP] 3 [/SUP], A A Lozhkov[SUP] 2 [/SUP], V V Vysochinskaya[SUP] 2 [/SUP], O A Dobrovolskaya[SUP] 3 [/SUP], O V Dovbysh[SUP] 4 [/SUP], E L Zimmerman[SUP] 2 [/SUP], P N Dav[SUP] 4 [/SUP], A V Brodskaia[SUP] 2 [/SUP], E I Sakhenberg[SUP] 3 [/SUP], A A Shaldzhyan[SUP] 3 [/SUP], A A Demaev[SUP] 4 [/SUP], M A Maslov[SUP] 5 [/SUP], A V Vasin[SUP] 2 [/SUP]
Affiliations
The emergence of new influenza virus strains presents a continuous challenge for global public health. mRNA technology offers a promising platform for rapidly developing therapeutics, particularly monoclonal antibodies, that can protect against viral infections. In this study, we engineered mRNA constructs encoding two types of antibodies: secreted antibodies specific to the hemagglutinin of the influenza A virus, based on previously characterized Fi6 antibodies, and intracellular Fab fragments targeting the nucleoprotein of the influenza B virus, derived from the 2/3 antibodies. The administration of mRNA constructs in vitro resulted in the successful synthesis of functional antibodies, which exhibited antiviral activity against influenza viruses. This study confirms the feasibility of using mRNA technology to develop therapeutic antibodies against influenza virus infections. The findings pave the way for future clinical applications of mRNA-based therapeutics, enhancing preparedness for emerging viral threats.
Keywords: Antibodies; Antivirals; Fab fragments; Influenza virus; mRNA therapeutics.
. 2024 Nov 3:738:150945.
doi: 10.1016/j.bbrc.2024.150945. Online ahead of print. mRNA encoding antibodies against hemagglutinin and nucleoprotein prevents influenza virus infection in vitro
Y A Zabrodskaya[SUP] 1 [/SUP], N V Gavrilova[SUP] 2 [/SUP], E A Elpaeva[SUP] 3 [/SUP], A A Lozhkov[SUP] 2 [/SUP], V V Vysochinskaya[SUP] 2 [/SUP], O A Dobrovolskaya[SUP] 3 [/SUP], O V Dovbysh[SUP] 4 [/SUP], E L Zimmerman[SUP] 2 [/SUP], P N Dav[SUP] 4 [/SUP], A V Brodskaia[SUP] 2 [/SUP], E I Sakhenberg[SUP] 3 [/SUP], A A Shaldzhyan[SUP] 3 [/SUP], A A Demaev[SUP] 4 [/SUP], M A Maslov[SUP] 5 [/SUP], A V Vasin[SUP] 2 [/SUP]
Affiliations
- PMID: 39504717
- DOI: 10.1016/j.bbrc.2024.150945
The emergence of new influenza virus strains presents a continuous challenge for global public health. mRNA technology offers a promising platform for rapidly developing therapeutics, particularly monoclonal antibodies, that can protect against viral infections. In this study, we engineered mRNA constructs encoding two types of antibodies: secreted antibodies specific to the hemagglutinin of the influenza A virus, based on previously characterized Fi6 antibodies, and intracellular Fab fragments targeting the nucleoprotein of the influenza B virus, derived from the 2/3 antibodies. The administration of mRNA constructs in vitro resulted in the successful synthesis of functional antibodies, which exhibited antiviral activity against influenza viruses. This study confirms the feasibility of using mRNA technology to develop therapeutic antibodies against influenza virus infections. The findings pave the way for future clinical applications of mRNA-based therapeutics, enhancing preparedness for emerging viral threats.
Keywords: Antibodies; Antivirals; Fab fragments; Influenza virus; mRNA therapeutics.